Welcome to our dedicated page for Enliven Therapeutics SEC filings (Ticker: ELVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Enliven Therapeutics SEC filings document a clinical-stage biopharmaceutical issuer developing small-molecule therapeutics, with disclosures centered on ELVN-001 for chronic myeloid leukemia and related operating results and cash resources. Current reports furnish quarterly and annual financial results and attach business updates describing ENABLE clinical-trial activity, regulatory-development topics, and program plans.
Proxy and governance filings describe annual meeting matters, board composition, committee leadership, executive transitions, director compensation, equity awards, and stockholder voting procedures. The filings also identify Enliven common stock on the Nasdaq Global Select Market and record material-event amendments when furnished press-release exhibits are corrected.
Enliven Therapeutics, Inc. (ELVN) reported that its Chief Financial Officer, Benjamin Hohl, sold shares of the company’s Common Stock in two open-market transactions on August 17, 2026. He sold 4,630 shares at a weighted average price of $58.3517 per share and 1,388 shares at a weighted average price of $59.3536 per share, totaling 6,018 shares. The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on March 18, 2026. A portion of the securities associated with his holdings are restricted stock units (RSUs), each representing a contingent right to receive one share of Common Stock, subject to vesting conditions.
Enliven Therapeutics, Inc. (ELVN) reported that Chief Medical Officer Helen Louise Collins exercised a stock option for 5,000 shares of common stock at an exercise price of $2.48 per share and on the same date sold 5,000 shares in two open-market transactions at weighted average prices of $58.3717 and $59.3465. Following the option exercise, she held 111,268 option shares directly. These transactions were effected under a Rule 10b5-1 trading plan adopted on October 19, 2025.
Enliven Therapeutics, Inc. director Mika K. Derynck exercised stock options covering 158,795 shares of common stock on August 4, 2026 at exercise prices of $2.4800, $14.8500, $22.4700 and $25.2800 per share.
He then sold 158,795 shares at a weighted average price of $60.2134 per share, in multiple trades between $60.00 and $60.58, pursuant to a Rule 10b5-1 trading plan adopted on April 8, 2025. All options exercised were fully vested and exercisable.
Enliven Therapeutics Inc. is the subject of an amended Schedule 13G filing (Amendment No. 3) reporting a significant ownership position by institutional investor FMR LLC and Abigail P. Johnson. FMR LLC reports that it beneficially owns 10,713,540.41 shares of Enliven common stock, representing 15.0% of the class.
FMR LLC has sole voting power over 10,704,808 shares and sole dispositive power over 10,713,540.41 shares, with no shared voting or dispositive power. Abigail P. Johnson is reported as having sole dispositive power over the same 10,713,540.41 shares and a 15.0% beneficial ownership interest. One or more other persons may receive dividends or sale proceeds from these shares, but no such person holds more than five percent of the outstanding common stock.
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on small-molecule precision therapies. The company is prioritizing ELVN-001 from its BCR-ABL program and preparations for a planned pivotal trial, while exploring strategic alternatives for ELVN-002 and discontinuing its development.
As of June 30, 2026, Enliven held $895.2 million in cash, cash equivalents and marketable securities and reported total stockholders’ equity of $895.1 million, with 73,270,761 common shares outstanding as of July 28, 2026. Management states this liquidity is expected to fund operating expenses and capital needs for at least 12 months.
For the quarter ended June 30, 2026, research and development expense was $28.996 million and general and administrative expense was $8.213 million, leading to a net loss of $32.485 million (basic and diluted net loss per share $0.49). For the first half of 2026, net loss was $56.112 million, with $21.312 million of stock-based compensation. A June 2026 underwritten offering raised aggregate gross proceeds of $460.0 million via common stock and pre-funded warrants, significantly strengthening the balance sheet.
Enliven Therapeutics, Inc. reported financial results for the second quarter ended June 30, 2026 and provided a business update. The company highlighted positive Phase 1 data for ELVN-001 in chronic myeloid leukemia, with a 61% overall major molecular response and 48% achieving major molecular response by 24 weeks at the 80 mg once-daily dose. Earlier-line patients showed 67% overall major molecular response and 55% by 24 weeks. As of the March 10, 2026 cutoff, 161 patients had been enrolled with a median treatment duration of 35 weeks and a favorable safety and tolerability profile.
Following an End-of-Phase 1 FDA meeting, 80 mg once daily was selected as the recommended Phase 3 dose for the planned ENABLE-2 second-line and later trial in CML patients previously treated with one or more TKIs, comparing ELVN-001 to physician’s choice of ATP-competitive TKI. ELVN-001 received Fast Track Designation, and ENABLE-2 is expected to start in the second half of 2026, with further Phase 3 design details to be finalized after a planned End-of-Phase 2 meeting anticipated in the third quarter of 2026.
Enliven reported a strong cash position, with $895.2 million in cash, cash equivalents and marketable securities as of June 30, 2026, expected to provide cash runway into 2030. Second-quarter 2026 research and development expenses were $29.0 million versus $21.5 million a year earlier, and general and administrative expenses were $8.2 million versus $7.1 million. Net loss for the quarter was $32.5 million, compared with $25.3 million in the second quarter of 2025, or $0.49 per share in both periods.
Enliven Therapeutics has filed a notice of proposed sale of common stock under Form 144, using Jefferies LLC as broker on NASDAQ. The filing lists multiple stock option positions in Enliven common stock, dated 08/09/2022, 02/23/2023, 02/13/2024, and 02/06/2025, each with specified amounts of common shares designated as securities to be sold.
Enliven Therapeutics CFO Benjamin Hohl reported an option exercise and related share sales on July 17, 2026. He exercised stock options covering 1,072 shares of common stock at an exercise price of $2.48 per share and sold 6,018 common shares in open-market transactions pursuant to a Rule 10b5-1 trading plan adopted on March 18, 2026. Following the exercise, he held 84,966 stock options for Enliven common stock.
Enliven Therapeutics’ chief medical officer Helen Louise Collins exercised stock options for 5,000 shares of common stock at $2.48 per share on July 17, 2026, then sold 5,000 shares in multiple trades at weighted average prices between $49.72 and $53.93. After the exercise, she reported directly holding 116,268 stock options. All transactions were effected under a pre-established Rule 10b5-1 trading plan adopted on October 19, 2025.
Helen Collins, a shareholder of Enliven Therapeutics, plans to sell up to 15,000 shares of common stock through Jefferies LLC, with an aggregate market value of $762,900.00. These 15,000 shares were acquired via stock options on 08/09/2022. Enliven Therapeutics had 71,000,000 common shares outstanding as of 07/17/2026; this is a baseline figure, not the amount being sold. Over the past three months, Collins sold 5,000 shares for $198,863.90 on 05/18/2026 and another 5,000 shares for $218,908.88 on 07/17/2026.